Quantcast
Channel: WN.com - Articles related to Actelion to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia (Actelion Ltd)
Viewing all articles
Browse latest Browse all 480

Initiation of Phase 1 Clinical Study with Novel Immuno-Oncology Candidate Triggers USD10 Million Milestone Payment from AstraZeneca to Heptares (Sosei Group Corporation)

$
0
0
(Source: Sosei Group Corporation) b01ce187-e6bd-4b0f-87f4-3319115b1bea.pdf Initiation of Phase 1 Clinical Study with Novel Immuno-Oncology Candidate Triggers US$10 Million Milestone Payment from AstraZeneca to Heptares Tokyo, Japan July 6 2016: Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) today announces Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation, reported that it has been notified today by its partner AstraZeneca that the first subject has been dosed with immuno-oncology candidate HTL1071 (AZD4635) in a Phase 1 clinical study, triggering a US$10 million payment from AstraZeneca. The first-in-human study is...

Viewing all articles
Browse latest Browse all 480

Trending Articles



<script src="https://jsc.adskeeper.com/r/s/rssing.com.1596347.js" async> </script>